Immunotherapy for early breast cancer: too soon, too superficial, or just right?

Immunotherapy emerged as a new treatment modality for breast cancer, and its use is approved in combination with chemotherapy for first-line therapy in metastatic triple-negative breast cancer overexpressing PD-L1. As immune checkpoint inhibitors alone have modest clinical activity in advanced breas...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2021-03, Vol.32 (3), p.323-336
Hauptverfasser:	Franzoi, M.A., Romano, E., Piccart, M.
Format:	Artikel
Sprache:	eng
Schlagworte:	clinical trials early breast cancer Humans Immunologic Factors Immunotherapy Triple Negative Breast Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!